Clinical effect of newly developed oral carbonaceous adsorbent (AST-120) in patients with advanced stages of chronic glomerulonephritis.
Clinical effects of a newly developed oral carbonaceous adsorbent (AST-120) in patients with advanced stages of chronic glomerulonephritis is described. Measurements of serum creatinine were performed before, during and after the administration of AST-120. The reciprocal of serum creatinine concentration was also plotted serially in each patient. The mean levels of the slope of the reciprocal serum creatinine vs time plot after administration of AST-120 was decreased compared with those before the administration of AST-120 but there was no statistical significance (p greater than 0.10). Further studies with more patients are needed to determine whether the administration of AST-120 may be useful for treatment of patients with chronic glomerulonephritis.